Drugs / 13 valent conjugated pneumococcal vaccine
13 valent conjugated pneumococcal vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03802994 | Nov 2018 → Feb 2020 | — | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03039491 | Sep 2015 → Mar 2020 | lipodystrophy | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13 valent conjugated pneumococcal vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03039491 ↗ |
| Known as | PCV-13 | “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ |
| Known as | Prevnar-13 | “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ |
| Modality | Vaccine | “This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197” NCT03039491 ↗ |